FR12C0059I2 - Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes - Google Patents

Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes

Info

Publication number
FR12C0059I2
FR12C0059I2 FR12C0059C FR12C0059C FR12C0059I2 FR 12C0059 I2 FR12C0059 I2 FR 12C0059I2 FR 12C0059 C FR12C0059 C FR 12C0059C FR 12C0059 C FR12C0059 C FR 12C0059C FR 12C0059 I2 FR12C0059 I2 FR 12C0059I2
Authority
FR
France
Prior art keywords
novel
soluble carbohydrates
moiety
immunogenic structures
produce immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0059C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Found For T
Original Assignee
Henry M Jackson Found For T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Found For T filed Critical Henry M Jackson Found For T
Publication of FR12C0059I1 publication Critical patent/FR12C0059I1/fr
Application granted granted Critical
Publication of FR12C0059I2 publication Critical patent/FR12C0059I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR12C0059C 1993-09-22 2012-10-18 Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes Active FR12C0059I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12449193A 1993-09-22 1993-09-22
PCT/US1994/010658 WO1995008348A1 (fr) 1993-09-22 1994-09-21 Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes

Publications (2)

Publication Number Publication Date
FR12C0059I1 FR12C0059I1 (fr) 2012-12-14
FR12C0059I2 true FR12C0059I2 (fr) 2016-10-21

Family

ID=22415196

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0059C Active FR12C0059I2 (fr) 1993-09-22 2012-10-18 Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes

Country Status (13)

Country Link
US (2) US5651971A (fr)
EP (1) EP0720485B1 (fr)
JP (1) JP3828145B2 (fr)
KR (1) KR100376361B1 (fr)
AT (1) ATE254475T1 (fr)
AU (1) AU678613B2 (fr)
CA (1) CA2171942C (fr)
DE (2) DE69433341T2 (fr)
ES (1) ES2210262T3 (fr)
FR (1) FR12C0059I2 (fr)
NL (2) NL300412I1 (fr)
NZ (1) NZ274376A (fr)
WO (1) WO1995008348A1 (fr)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
US5849301A (en) * 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
AU712981B2 (en) * 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
WO1996032963A1 (fr) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Declenchement et renforcement de la reaction immunitaire aux polysaccharides a l'aide de lipoproteines bacteriennes
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6447777B1 (en) * 1996-03-29 2002-09-10 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
BR9709993A (pt) 1996-06-25 1999-08-10 Stichting Inst Dierhouderij Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6087328A (en) * 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
AU3005499A (en) * 1998-03-16 1999-10-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
ATE364395T1 (de) * 1998-04-10 2007-07-15 Andrew Lees Konjugat-impfstoffe zur vorbeugung der zahnkaries
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999064603A2 (fr) * 1998-06-12 1999-12-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine AUGMENTATION DE L'ACTIVATION DES CELLULES B ET DE LA SECRETION D'IMMUNOGLOBULINE PAR CO-STIMULATION DE RECEPTEURS DE L'ANTIGENE ET D'EBV Gp350/220
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2714833A1 (fr) * 1998-07-20 2000-02-03 Edward Konadu (Deceased) Vaccins contre l'infection due a l'escherichia coli o157
US6585973B1 (en) 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DK1296715T4 (en) 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
WO2004080490A2 (fr) * 2003-03-07 2004-09-23 Wyeth Holdings Corporation Conjugues de proteine-polysaccharide porteuse d'adhesine superficielle staphylococcique pour immunisation contre des infections nosocomiales
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CA2556169C (fr) * 2004-01-29 2011-11-22 Andrew Lees Utilisation de groupes fonctionnels amino-oxy dans la preparation de vaccins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US9402915B2 (en) 2004-04-30 2016-08-02 Glaxosmithkline Biologicals Sa Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7456000B2 (en) * 2004-08-26 2008-11-25 Siemens Healthcare Diagnostics Inc. Deactivation of linking moieties in antibody-enzyme conjugates
EP2298340B1 (fr) 2004-09-22 2014-04-16 GlaxoSmithKline Biologicals S.A. Composition immunogène pour la vaccination contre des staphylocoques
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
EP2425853A1 (fr) 2005-04-08 2012-03-07 Wyeth LLC Composition conjuguée polysaccharide-protéine pneumococcique polyvalente
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
BRPI0620460B8 (pt) 2005-12-22 2021-05-25 Glaxosmithkline Biologicals Sa uso de composição imunogênica para bebês, e, processo para produzir uma vacina
CN101405028B (zh) 2006-03-17 2015-08-19 美国政府健康及人类服务部 制备复合的多价免疫原性结合物的方法
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (fr) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Compositions immunogènes et procédés
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2886551A3 (fr) 2008-02-21 2015-09-23 Novartis AG Polypeptides fHbp méningococciques
WO2010042481A1 (fr) 2008-10-06 2010-04-15 University Of Chicago Compositions et procédés associés aux protéines bactériennes eap, emp, et/ou adsa
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP3281947B1 (fr) 2009-04-03 2020-02-12 The University of Chicago Compositions et procédés liés aux variantes de la protéine a (spa)
WO2010135714A2 (fr) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Méthodes de modulation de l'expression des adipocytes utilisant des compositions de micro-arn
WO2010141312A2 (fr) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Protéines de fusion flagelline et conjugués comprenant des antigènes pneumocoques et leurs procédés d'utilisation
SA114350400B1 (ar) 2009-06-22 2016-05-26 ويث ال ال سي تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
WO2011036560A2 (fr) 2009-09-23 2011-03-31 Novartis Ag Compositions de glycoconjugués et méthodes pour le traitement du vih
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
CA2836140C (fr) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Reactifs chimiques pour l'activation des polysaccharides dans la preparation de vaccins conjugues
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
EP2555794A4 (fr) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS ET PROCÉDÉS LIÉS AUX ANTICORPS DE LA PROTÉINE A (SpA) EN TANT QUE AMPLIFICATEUR DE LA RÉPONSE IMMUNITAIRE
US8383783B2 (en) 2010-04-23 2013-02-26 Serum Institute Of India, Ltd. Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013068949A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
CA2886938A1 (fr) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
WO2014102265A1 (fr) 2012-12-27 2014-07-03 Glycovaxyn Ag Procédés et compositions se rapportant à crm197
CN105007936B (zh) 2013-03-08 2018-10-02 扬森疫苗与预防公司 无细胞百日咳疫苗
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN105636608A (zh) * 2013-10-11 2016-06-01 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 免疫原性增强的多糖-蛋白质缀合物及其快速高产的制备方法
WO2015095868A1 (fr) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Méthodes et compositions permettant d'augmenter les taux d'anticorps protecteurs induits par des vaccins antipneumococciques polyosidiques
KR20210032013A (ko) 2014-01-21 2021-03-23 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PT3096785T (pt) 2014-01-21 2020-10-13 Pfizer Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
JP2017510290A (ja) 2014-01-31 2017-04-13 フィナ バイオソリューションズ リミテッド ライアビリティ カンパニー Ｃｒｍ１９７および関連タンパク質の発現および精製
CA2940447C (fr) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Polypeptides fhbp meningococciques modifies
EP2921856B1 (fr) 2014-03-18 2016-09-14 Serum Institute Of India Private Limited Analyse quantitative pour de la 4-pyrrolidinopyridine (4-ppy) dans des vaccins conjugués polyssacharide-protéine
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3229833A1 (fr) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Procédé de traitement
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
EP3244917B1 (fr) 2015-01-15 2023-04-19 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins antipneumococciques
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
DK3313436T3 (da) 2015-06-23 2021-03-08 Biological E Ltd Multivalent pneumokok-konjugatvaccine
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (fr) 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
US11191822B2 (en) 2016-06-22 2021-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI770044B (zh) 2016-08-05 2022-07-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
WO2018042015A1 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
KR101991457B1 (ko) * 2016-09-06 2019-09-30 주식회사 엘지화학 다가 협막 다당류-운반 단백질을 포함하는 조성물 및 이의 용도
PH12019500672B1 (en) 2016-09-30 2024-02-23 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysachharide-protein conjugates
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102701633B1 (ko) 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112020004509A8 (pt) 2017-09-07 2023-01-31 Merck Sharp & Dohme Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
BR112020011414B8 (pt) 2017-12-06 2023-01-31 Merck Sharp & Dohme Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
KR20230008923A (ko) 2018-02-05 2023-01-16 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
BR112020014978A2 (pt) 2018-02-05 2020-12-22 Sanofi Pasteur, Inc. Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
US12018134B2 (en) 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp
AU2019341723C1 (en) 2018-09-23 2026-01-22 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
WO2020075201A1 (fr) 2018-10-12 2020-04-16 Biological E Limited Vaccin conjugué polysaccharide pneumococcique-protéine multivalent
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
JP7585203B2 (ja) 2018-12-12 2024-11-18 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
EP3897705A2 (fr) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
EP3923982A1 (fr) 2019-02-11 2021-12-22 Pfizer Inc. Compositions de neisseria meningitidiset procédés associées
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (fr) 2019-04-10 2020-10-15 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
WO2020229964A1 (fr) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Production de conjugués
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
EP3757217A1 (fr) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Procédés de purification de protéines
PH12022550110A1 (en) 2019-07-31 2022-12-12 Sk Bioscience Co Ltd Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP4034157A1 (fr) 2019-09-27 2022-08-03 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
BR112022008761A2 (pt) 2019-11-22 2022-07-26 Glaxosmithkline Biologicals Sa Dosagem e administração de uma vacina de glicoconjugado de sacarídeo
MX2022010355A (es) 2020-02-21 2022-09-21 Pfizer Purificacion de sacaridos.
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
CA3185429A1 (fr) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Immunisation bacterienne a l'aide d'un vaccin a nanoparticules
BR112022023234A2 (pt) 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CA3192786A1 (fr) 2020-08-26 2022-03-03 Pfizer Inc. Conjugues polysaccharide-proteine de streptococcus du groupe b, procedes de production de conjugues, compositions immunogenes comprenant les conjugues et leurs utilisations
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
US20230405104A1 (en) 2020-10-20 2023-12-21 Shanghai Reinovax Biologics Co., Ltd Proteoglycan conjugate and application thereof
EP4232593A1 (fr) 2020-10-22 2023-08-30 Pfizer Inc. Procédés de purification de polysaccharides bactériens
CA3200602A1 (fr) 2020-11-04 2022-05-12 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
EP4452308A1 (fr) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccin
CN116942804A (zh) 2022-04-19 2023-10-27 上海瑞宙生物科技有限公司 多价肺炎球菌多糖结合疫苗的成分及其应用
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
CN114965784B (zh) * 2022-06-01 2023-10-27 艾美探索者生命科学研发有限公司 多糖活化度的测定方法
IL321062A (en) 2022-11-22 2025-07-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko) 2022-12-01 2025-07-25 화이자 인코포레이티드 폐렴구균 접합체 백신 제형
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
CN121038808A (zh) 2023-03-30 2025-11-28 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
EP4713008A2 (fr) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Procédés de déclenchement d'une réponse immunitaire contre une infection par le virus respiratoire syncycial et streptococcus pneumoniae
WO2025032534A2 (fr) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Protéines modifiées
KR20260051063A (ko) 2023-08-09 2026-04-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
CN118620072A (zh) 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用
WO2025172892A1 (fr) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Protéines modifiées et méthodes
WO2025186705A2 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2026038177A1 (fr) 2024-08-16 2026-02-19 Pfizer Inc. Compositions immunogènes et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (fr) * 1967-12-20 1972-03-06 Pharmacia Ab
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
DE3540076A1 (de) * 1985-11-12 1987-05-14 Boehringer Mannheim Gmbh Verfahren zur stabilisierung von creatinkinase
DE3541186A1 (de) * 1985-11-21 1987-05-27 Boehringer Mannheim Gmbh Wasserloesliche, stabilisierte peroxidasederivate, verfahren zu ihrer herstellung und verwendung zur bestimmung von wasserstoffperoxid
ATE111746T1 (de) * 1989-11-15 1994-10-15 Sandoz Ag Polymyxinkonjugate.
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
AU685047B2 (en) * 1992-02-11 1998-01-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
ES2210262T3 (es) * 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.

Also Published As

Publication number Publication date
CA2171942C (fr) 2010-12-14
NZ274376A (en) 1997-11-24
DE69433341D1 (de) 2003-12-24
NL300411I1 (nl) 2009-12-01
JPH09502978A (ja) 1997-03-25
ATE254475T1 (de) 2003-12-15
AU678613B2 (en) 1997-06-05
NL300412I1 (nl) 2009-12-01
KR960704572A (ko) 1996-10-09
FR12C0059I1 (fr) 2012-12-14
WO1995008348A1 (fr) 1995-03-30
ES2210262T3 (es) 2004-07-01
DE122009000058I1 (de) 2009-12-31
DE69433341T2 (de) 2004-04-15
JP3828145B2 (ja) 2006-10-04
EP0720485A1 (fr) 1996-07-10
AU7839194A (en) 1995-04-10
US5693326A (en) 1997-12-02
CA2171942A1 (fr) 1995-03-30
US5651971A (en) 1997-07-29
EP0720485B1 (fr) 2003-11-19
KR100376361B1 (ko) 2003-07-18

Similar Documents

Publication Publication Date Title
CA2215933A1 (fr) Preparation de produits de recombinaison immunogenes au moyen d'hydrates de carbone solubles actives par l'intermediaire de reactifs organiques de cyanylation
FR12C0059I1 (fr)
WO1995008348B1 (fr) Procede permettant d'activer un glucide soluble a l'aide de nouveaux reactifs cyanylants pour produire des structures immunogenes
EG15882A (en) Procede de preparation de nouveaux conjuges associants,par liaison covalente,une enzyme et un anticorps
DE69826851T2 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
HK1044288A1 (zh) 制造5'核酸蛋白质结合的方法
ATE246702T1 (de) Verfahren zur darstellung von oligonukleotiden
DK372186D0 (da) Polysaccharidpolymer samt fremgangsmaade til fremstilling heraf og mikrobiologisk ren xanthomonas-kultur
DK0865484T3 (da) Hidtil ukendt xylanasesammensætning og fremgangsmåde til fremstilling deraf
KR830008684A (ko) 면역 글로불린 접합체의 제조방법
ATE285790T1 (de) Herstellungsverfahren von festphasekonjugateimpfstoffen
EP0301522A3 (fr) Procédé de préparation d'isomaltulose
NO992710L (no) FremgangsmÕte for fremstilling av metallkomplekskarboksylsyreamider
IS4071A (is) N-Asetýl Neuraminic sýra og aðferð til framleiðslu á henni
ATE161051T1 (de) Verfahren zur herstellung aktivierter sialinsäuren
NO920163L (no) Hydrolysert vegetabilsk protein og fremstilling av et slikt
AU5045493A (en) Process for preparing conjugates consisting of a specific binding partner and a carbohydrate-containing protein
EA199700325A1 (ru) Способ получения стрептограминов и производные стрептограминов
JPS6486894A (en) Fermentation method for obtaining xanthan polysaccharide and product obtained thereby
EP0261416A3 (fr) Méthode de détection de 1,2,2-triméthylpropyl méthylphosphofluoridate
KR890009416A (ko) 정제된 백일해 특소이드의 제조방법
ES2074935A1 (es) Proteina ebulina 1 de la planta sambucus ebulus l., procedimiento para su obtencion y su utilizacion.
RU96101631A (ru) Способ получения вакцины
KR890010036A (ko) 폴리이소부틸렌 호박산 이미드의 제조방법
KR880011195A (ko) N-(4-시아노/니트로페닐이소티오카바모일)-l-아스파틸-l-페닐알라닌메틸에스테르의 제조방법